
Praxis Precision Medicines (PRAX) shares nearly tripled on Thursday after the biotechnology firm reported promising late-stage results for its experimental drug ulixacaltamide.
According to the company’s press release, ulixacaltamide significantly improved daily functioning in patients with essential tremor across two Phase 3 trials.